In the treatment of advanced prostate cancer (PCa), researchers found that SLC4A4 can mediate the lactylation of p53 through the NF-κB/STAT3/SLC4A4 axis, which eventually leads to the development of enzalutamide resistance and the progression of PCa [86]. The gene discussed is TP53; the disease is posterior cortical atrophy.